In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: Optimization of a coculture model for personalized therapy approaches

Molecular Cancer Therapeutics

Volumn 6, Issue 12, 2007, Pages 3091-3100

  Veneziani, Bianca Maria ^a,c   Criniti, Vittoria ^a   Cavaliere, Carla ^a   Corvigno, Sara ^a   Nardone, Agostina ^a   Picarelli, Silvia ^a   Tortora, Giampaolo ^a,c   Ciardiello, Fortunato ^a,c   Limite, Gennaro ^b   De Placido, Sabino ^a,c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Oncotech   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AROMATASE; CYTOKERATIN; EPIDERMAL GROWTH FACTOR; FORMESTANE; TRASTUZUMAB; VIMENTIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL EXPANSION; CENTRIFUGATION; COCULTURE; CONTROLLED STUDY; CRYOPRESERVATION; DOSE RESPONSE; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYME CELL; MOLECULAR THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; WESTERN BLOTTING;

ANDROSTENEDIONE; ANTIBODIES, MONOCLONAL; AROMATASE; AROMATASE INHIBITORS; BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CRYOPRESERVATION; DNA PRIMERS; EPITHELIAL CELLS; HUMANS; MESODERM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS;

EID: 37549007243     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0356     Document Type: Article

References (34)

1. Hanahan D, Weinberg RA. The hallmarks of cancer [review]. Cell 2000;100:57-70.
2. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression [review]. Nature 2004;432:332-7.
3. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation [review]. Exp Cell Res 2001;264:169-84.
4. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer [review]. Nat Rev Cancer 2004;4:839-49.
5. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type [review]. Cell Cycle 2006;5:1597-601.
6. Kalluri R, Zeisberg M. Fibroblasts in cancer [review]. Nat Rev Cancer 2006;6:392-401.
7. De Placido S, Carlomagno C, De Laurentiis M, Bianco AR. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients [review]. Breast Cancer Res Treat 1998;52:55-64.
8. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thurlimann B, Senn HJ; St Gallen Expert Panel Members. First - select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 2006;17:1772-6.
9. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
10. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741-8.
11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
12. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
13. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER. Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J Clin Endocrinol Metab 1981;53:412-7.
14. Simpson ER, Misso M, Hewitt KN, et al. Estrogen - the good, the bad, and the unexpected. Endocr Rev 2005;26:322-30.
15. Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy [review]. Lancet Oncol 2005;6:780-9.
16. Speirs V, Green AR, Walton DS, et al. Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer 1998;78:1421-9.
17. Heneweer M, Muusse M, Dingemans M, de Jong PC, van den Berg M, Sanderson JT. Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Toxicol Sci 2005;83:257-63.
18. Krasna L, Dudorkinova D, Vedralova J, et al. Large expansion of morphologically heterogeneous mammary epithelial cells, including the luminal phenotype, from human breast tumours. Breast Cancer Res Treat 2002;71:219-35.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
21. Crescenzi E, Chiaviello A, Canti G, Reddi E, Veneziani BM, Palumbo G. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lungcancer cells (H1299). Mol Cancer Ther 2006;5:776-85.
22. Morelli MP, Cascone T, Troiani T, et al. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blockingmonoclon al antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 2006;208:344-53.
23. Crescenzi E, Varriale L, Iovino M, Chiaviello A, Veneziani BM, Palumbo G. Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells. Mol Cancer Ther 2004;3:537-44.
24. Sanderson JT, Boerma J, Lansbergen GW, van den Berg M. Induction and inhibition of aromatase (CYP19) activity by various classes of pesticides in H295R human adrenocortical carcinoma cells. Toxicol Appl Pharmacol 2002;182:44-54.
25. Tallarida RJ. Interactions between drugs and occupied receptors [review]. Pharmacol Ther 2007;113:197-209.
26. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-73.
27. Herbst RS, Lippman SM. Molecular signatures of lung cancer - toward personalized therapy. N Engl J Med 2007;356:76-8.
28. Tuma RS. Researchers may use cancer cell lines to identify target populations prior to clinical trials. J Natl Cancer Inst 2006;98:810-1.
29. Zaleski J, Richburg J, Kauffman FC. Preservation of the rate and profile of xenobiotic metabolism in rat hepatocytes stored in liquid nitrogen. Biochem Pharmacol 1993;46:111-6.
30. Silva JM, Khan S, O'Brien PJ. Contrastingmo lecular cytotoxic mechanisms of mitomycin C and its two analogs, BMY 25282 and BMY 25067, in isolated rat hepatocytes. Biochem Pharmacol 1993;45:2303-9.
31. Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E, Czerwenka K. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 2003;80:353-61.
32. Burden S, Yarden Y. Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis [review]. Neuron 1997;18:847-55.
33. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 1999;19:6845-57.
34. Zhuang YH, Saaristo R, Ylikomi T. An in vitro long-term culture model for normal human mammary gland: expression and regulation of steroid receptors. Cell Tissue Res 2003;311:217-26.